FOTIVDA 0.89 MG Oral Capsule
- RxCUI
- 2534244
- RxNorm name
- FOTIVDA 0.89 MG Oral Capsule
- Display name
- FOTIVDA 0.89 MG Oral Capsule
- Full name
- FOTIVDA 0.89 MG Oral Capsule
- Term type
- PSN
- Status
- DailyMed mapping
- Updated
- 2026-06-04 23:39:24
UNII Substances#
No records found.
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| FOTIVDA | TIVOZANIB | AVEO Pharmaceuticals, Inc. | de77155c-ecf2-4f15-9758-21d271449d83 | 2026-09-15 | Warnings, Adverse reactions | 2534244 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
DailyMed RxNorm Mappings#
| Set ID | RxNorm mappings | Terms | SPL version | Label | Effective |
|---|---|---|---|---|---|
| de77155c-ecf2-4f15-9758-21d271449d83 | FOTIVDA 0.89 MG Oral Capsule [PSN] · tivozanib 0.89 MG Oral Capsule [Fotivda] [SBD] · Fotivda (as tivozanib hydrochloride 1 MG) 0.89 MG Oral Capsule [SY] · Fotivda 0.89 MG Oral Capsule [SY] | 4 | 13 | These highlights do not include all the information needed to use FOTIVDA safely and effectively. See full prescribing information for FOTIVDA. FOTIVDA ® (tivozanib) capsules, for oral use Initial U.S. Approval: 2021 | 20251001 |